Literature DB >> 17180728

Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein.

Tanja Obradovic1, Glenn G Dobson, Tomotaka Shingaki, Thomas Kungu, Ismael J Hidalgo.   

Abstract

PURPOSE: The sedating effect of first generation H(1)-antihistamines has been associated with their ability to penetrate the blood-brain barrier (BBB) and lack of efflux by P-glycoprotein (Pgp). Second generation H(1)-antihistamines are relatively free of sedation and their limited brain penetration has been suggested to arise from Pgp-mediated efflux. The objective of this work was to evaluate the role of Pgp in brain penetration of first and second generation antihistamines.
METHODS: Potential of antihistamines to be Pgp substrates was tested in vitro using Madin Darby canine kidney cells transfected with human Pgp. The role of Pgp in limiting brain penetration of antihistamines was tested by using the in situ brain perfusion technique.
RESULTS: Majority of antihistamines were Pgp substrates in vitro. Following in situ brain perfusion, the first generation antihistamines substantially penetrated into rat brain independently from Pgp function. The second generation antihistamines terfenadine and loratadine, achieved substantial brain penetration, which was further enhanced by Pgp inhibition by cyclosporin A (CSA). In contrast, fexofenadine and cetirizine, penetrated brain poorly regardless of CSA administration.
CONCLUSIONS: Antihistamines greatly differ in their ability to cross the BBB as well as in the role of Pgp in limiting their transport into the CNS in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17180728     DOI: 10.1007/s11095-006-9149-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  42 in total

Review 1.  Prediction of intestinal absorption and blood-brain barrier penetration by computational methods.

Authors:  D E Clark
Journal:  Comb Chem High Throughput Screen       Date:  2001-09       Impact factor: 1.339

Review 2.  Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system.

Authors:  Q R Smith
Journal:  Pharm Biotechnol       Date:  1996

3.  Is there a difference in the affinity of histamine H1 receptor antagonists for CNS and peripheral receptors? An in vitro study.

Authors:  A M Ter Laak; G M Donné-Op den Kelder; A Bast; H Timmerman
Journal:  Eur J Pharmacol       Date:  1993-03-02       Impact factor: 4.432

4.  Transport characteristics of diphenhydramine in human intestinal epithelial Caco-2 cells: contribution of pH-dependent transport system.

Authors:  H Mizuuchi; T Katsura; H Saito; Y Hashimoto; K I Inui
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

5.  Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain.

Authors:  Scott G Summerfield; Alexander J Stevens; Leanne Cutler; Maria del Carmen Osuna; Beverley Hammond; Sac-Pham Tang; Ann Hersey; David J Spalding; Phil Jeffrey
Journal:  J Pharmacol Exp Ther       Date:  2005-12-05       Impact factor: 4.030

6.  Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

Authors:  Kelly M Mahar Doan; Joan E Humphreys; Lindsey O Webster; Stephen A Wring; Larry J Shampine; Cosette J Serabjit-Singh; Kimberly K Adkison; Joseph W Polli
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

7.  P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.

Authors:  Harunobu Tahara; Hiroyuki Kusuhara; Eiichi Fuse; Yuichi Sugiyama
Journal:  Drug Metab Dispos       Date:  2005-04-08       Impact factor: 3.922

8.  P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.

Authors:  Cuiping Chen; Elizabeth Hanson; John W Watson; Jae S Lee
Journal:  Drug Metab Dispos       Date:  2003-03       Impact factor: 3.922

9.  Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.

Authors:  Salvatore Cisternino; Claire Mercier; Fanchon Bourasset; Françoise Roux; Jean-Michel Scherrmann
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

10.  Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography.

Authors:  K Yanai; J H Ryu; T Watanabe; R Iwata; T Ido; Y Sawai; K Ito; M Itoh
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

View more
  24 in total

Review 1.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Authors:  Fabio Broccatelli; Caroline A Larregieu; Gabriele Cruciani; Tudor I Oprea; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2011-12-21       Impact factor: 15.470

2.  A new in situ brain perfusion flow correction method for lipophilic drugs based on the pH-dependent Crone-Renkin equation.

Authors:  Alex Avdeef; Na Sun
Journal:  Pharm Res       Date:  2010-11-02       Impact factor: 4.200

Review 3.  Targeting protein kinases in central nervous system disorders.

Authors:  Laura K Chico; Linda J Van Eldik; D Martin Watterson
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

Review 4.  The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation.

Authors:  Li Di; Amanda Balesano; Samantha Jordan; Sophia M Shi
Journal:  AAPS J       Date:  2021-01-07       Impact factor: 4.009

Review 5.  Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.

Authors:  Michael B Chancellor; David R Staskin; Gary G Kay; Bobby W Sandage; Michael G Oefelein; Jack W Tsao
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

6.  First-trimester antihistamine exposure and risk of spontaneous abortion or preterm birth.

Authors:  Tiara D Aldridge; Katherine E Hartmann; Kara A Michels; Digna R Velez Edwards
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-05-01       Impact factor: 2.890

Review 7.  Bilastine: in allergic rhinitis and urticaria.

Authors:  Natalie J Carter
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

8.  Differential effects of functionally different histamine H4 receptor ligands on acute irritant dermatitis in mice.

Authors:  Maristella Adami; Cristina Micheloni; Daniela Grandi; Holger Stark
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-25       Impact factor: 3.000

9.  Assessment of blood-brain barrier permeability using the in situ mouse brain perfusion technique.

Authors:  Rong Zhao; J Cory Kalvass; Gary M Pollack
Journal:  Pharm Res       Date:  2009-04-22       Impact factor: 4.200

10.  Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration.

Authors:  Rong Zhao; J Cory Kalvass; Souzan B Yanni; Arlene S Bridges; Gary M Pollack
Journal:  Drug Metab Dispos       Date:  2008-12-29       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.